

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-6. (Canceled)

7. (Currently amended) [[An]] A full length infectious and genetically stable [[JEV]] cDNA clone of Japanese encephalitis virus (JEV) for the full length JEV genomic RNA of claim 1.

8. (Currently amended) The [[JEV]] cDNA clone as set forth in claim 7, wherein the cDNA clone contains a promoter at the beginning of 5' end of a DNA sequence corresponding to a JEV genomic RNA and a restriction endonuclease recognition sequence at the end of 3' end of the DNA sequence as a runoff site.

9. (Currently amended) The [[JEV]] cDNA clone as set forth in claim 8, wherein the promoter is SP6 or T7.

10. (Currently amended) The [[JEV]] cDNA clone as set forth in claim 8, wherein the restriction endonuclease recognition sequence is not exist in the JEV genomic RNA.

11. (Currently amended) The [[JEV]] cDNA clone as set forth in claim 8, wherein the restriction endonuclease recognition sequence is *Xho* I or *Xba* I.

12. (Currently amended) The [[JEV]] cDNA clone as set forth in claim 8, wherein the [[JEV]] cDNA clone is selected from a group consisting of sequences represented by SEQ. ID. No 43, No 44, and No 45, which all have SP6 promoter and sequences represented by SEQ. ID. No 46, No 47, and No 48, which all have T7 promoter.

13. (Currently amended) A vector including the [[JEV]] cDNA clone ~~for the full-length JEV genomic RNA~~ of claim 7.

14. (Currently amended) The vector as set forth in claim 13, wherein ~~a the vector used~~ bacterial artificial chromosome (BAC) [[as]] is used for a parental vector.

15. (Original) The vector as set forth in claim 13, wherein the vector is selected from a group consisting of pBAC^{SP6}/JVFL/*Xho*I containing the JEV cDNA represented by SEQ. ID. No 43, pBAC^{SP6}/JVFLx/*Xho*I containing the JEV cDNA represented by SEQ. ID. No 44, pBAC^{SP6}/JVFLx/*Xba*I containing the JEV cDNA represented by SEQ. ID. No 45, pBAC^{T7}/JVFL/*Xho*I containing the JEV cDNA represented by SEQ. ID. No 46, pBAC^{T7}/JVFLx/*Xho*I containing the JEV cDNA represented by SEQ. ID. No 47, and pBAC^{T7}/JVFLx/*Xba*I containing the JEV cDNA represented by SEQ. ID. No 48.

16. (Original) The vector as set forth in claim 15, wherein the vector is pBAC^{T7}/JVFLx/XbaI having T7 promoter (Accession No : KCTC 10346BP).

17. (Original) The vector as set forth in claim 15, wherein the vector is pBAC^{SP6}/JVFLx/XbaI having SP6 promoter (Accession No : KCTC 10347BP).

18. (Currently amended) An infectious JEV RNA transcript synthesized from the cDNA clone vector of claim ~~[[13]]~~ 7.

19. (Currently amended) ~~[[An]]~~ The infectious JEV RNA transcript as set forth in claim 18, wherein ~~[[the]]~~ virus-unrelated nucleotides at its 3' end are removed.

20. (Currently amended) ~~[[An]]~~ The infectious JEV RNA transcript as set forth in claim 19, wherein the virus-unrelated nucleotides are removed by treating mung bean nuclease (MBN).

21. (Original) A cell transfected with the JEV RNA transcript of claim 18.

22. (Original) A synthetic JEV obtained by cultivation of the cell of claim 21.

23. (Currently amended) A synthetic JEV as set forth in claim 22, wherein ~~[[the]]~~ a mutation is introduced in the JEV cDNA.

24. (Currently amended) A method for the expression of heterologous genes using the cDNA clone of claim 8 comprising the following steps:

- 1) ~~Preparing~~ preparing a recombinant JEV cDNA expression vector by inserting heterologous genes into the [[JEV]] cDNA clone ~~vector~~ of claim [[13]] 8;
- 2) ~~Producing~~ producing a JEV RNA transcript from the above recombinant JEV cDNA expression vector;
- 3) ~~Preparing~~ preparing a cell transfected with the above JEV RNA transcript; and
- 4) ~~Expressing~~ expressing foreign proteins by culturing the above cell.

25. (Original) The method as set forth in claim 24, wherein the foreign genes are inserted at the beginning of the JEV 3'NTR of the JEV cDNA.

26. (Currently amended) A diagnostic reagent containing elements originated from the ~~JEV genomic RNA or JEV cDNA~~ clone of claim 7.

27. (Currently amended) An anti-JEV vaccine containing elements originated from the ~~JEV genomic RNA or JEV cDNA~~ clone of claim 7 or the synthetic JEV of claim 22.

28. (Original) A therapeutic agent comprising the JEV cDNA of claim 7 as effective ingredients.

28. (New) The cDNA clone as set forth in claim 8, wherein the JEV genomic RNA consists of a 5' nontranslated region (NTR), a single polypeptide coding region, and a 3' NTR.